Candesartan

Generic Name
Candesartan
Brand Names
Atacand, Atacand Hct
Drug Type
Small Molecule
Chemical Formula
C24H20N6O3
CAS Number
139481-59-7
Unique Ingredient Identifier
S8Q36MD2XX
Background

Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.

Indication

May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction an...

Associated Conditions
Hypertension, NYHA Functional Class II-IV Heart Failure
Associated Therapies
-
Clinical Trials
Related News

Angiotensin II Antagonism of TGF-Beta 1

Not Applicable
Completed
Conditions
Hypertension
Diabetic Nephropathy
First Posted Date
2006-05-03
Last Posted Date
2007-08-02
Lead Sponsor
Providence Health & Services
Target Recruit Count
36
Registration Number
NCT00320970
Locations
🇺🇸

Providence Medical Research Center, Spokane, Washington, United States

Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism of Obese Subjects

Phase 4
Terminated
Conditions
Glucose Intolerance
Obesity
Interventions
Drug: Candesartan
Drug: Placebo
First Posted Date
2006-04-27
Last Posted Date
2012-11-06
Lead Sponsor
Fundación Cardiovascular de Colombia
Target Recruit Count
56
Registration Number
NCT00319202
Locations
🇨🇴

Fundación Cardiovascular de Colombia, Floridablanca, Santander, Colombia

Effect of Angiotensin II Receptor Blockers (ARB) on Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis

First Posted Date
2006-02-22
Last Posted Date
2009-06-30
Lead Sponsor
Odense University Hospital
Target Recruit Count
140
Registration Number
NCT00294775
Locations
🇩🇰

Cardiology Department, Odense University hospital, Odense, Fyn, Denmark

Effectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese Patients

Not Applicable
Conditions
Hypertension
First Posted Date
2006-02-08
Last Posted Date
2007-01-11
Lead Sponsor
Saitama Medical University
Target Recruit Count
300
Registration Number
NCT00288717
Locations
🇯🇵

Saitama Medical School Department of Renal Medicine, Saitama City, Saitama, Japan

Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo

First Posted Date
2006-01-25
Last Posted Date
2008-10-16
Lead Sponsor
Umeå University
Target Recruit Count
26
Registration Number
NCT00282178
Locations
🇸🇪

Umeå University Hospital, Umeå, Sweden

Diabetic Retinopathy Candesartan Trials

Phase 3
Completed
Conditions
Type 1 Diabetes
Interventions
Drug: candesartan cilexetil
First Posted Date
2005-11-15
Last Posted Date
2014-05-14
Lead Sponsor
AstraZeneca
Target Recruit Count
5238
Registration Number
NCT00252733
Locations
🇩🇰

Research Site, Odense, Denmark

DIabetic Retinopathy Candesartan Trials

Phase 3
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: candesartan
First Posted Date
2005-11-15
Last Posted Date
2014-06-06
Lead Sponsor
AstraZeneca
Target Recruit Count
4717
Registration Number
NCT00252694

DIabetic Retinopathy Candesartan Trials.

Phase 3
Completed
Conditions
Type 1 Diabetes
Interventions
Drug: candesartan
First Posted Date
2005-11-15
Last Posted Date
2014-06-03
Lead Sponsor
AstraZeneca
Target Recruit Count
1850
Registration Number
NCT00252720

High Doses of Candesartan Cilexetil on the Reduction of Proteinuria

Phase 3
Completed
Conditions
Proteinuria
First Posted Date
2005-10-20
Last Posted Date
2007-12-19
Lead Sponsor
AstraZeneca
Target Recruit Count
270
Registration Number
NCT00242346
Locations
🇨🇦

Research Site, Saskatoon, Saskatchewan, Canada

TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial

Phase 3
Completed
Conditions
Hypertension
First Posted Date
2005-09-28
Last Posted Date
2011-08-30
Lead Sponsor
AstraZeneca
Target Recruit Count
1000
Registration Number
NCT00227318
Locations
🇺🇸

Research Site, Milwaukee, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy